ELVN position history
The shares of Enliven Therapeutics (ELVN) that Avidity Partners Management LP reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2025 Q1: 11,300 shares, $222K, 0.04% of portfolio, New
- 2025 Q2: 11,300 shares, $227K, 0.05% of portfolio
- 2025 Q3: 140,300 shares, $2.9M, 0.65% of portfolio, Add +1141.6%
- 2025 Q4: 140,300 shares, $2.2M, 0.62% of portfolio
- 2026 Q1: 800,000 shares, $32M, 3.7% of portfolio, Add +470.2%
- 2026 Q2: 550,000 shares, $28M, 4.5% of portfolio, Reduce −31.3%
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|